Literature DB >> 2156943

Epstein-Barr virus and other herpesvirus infections in Kawasaki syndrome.

N J Marchette1, M E Melish, R Hicks, S Kihara, E Sam, D Ching.   

Abstract

Epstein-Barr virus (EBV), a possible cause of Kawasaki syndrome (KS), is not pathenogenically associated with KS in Hawaii. The prevalence of EBV capsid antibody in KS patients was found not to differ significantly from that in controls, and the antibody response in those infected with EBV was the same as that in other children similarly infected. No EBV was isolated from acute-phase patients. All patients with capsid antibody at the onset of KS also had Epstein-Barr nuclear antigen antibody: 36 patients developed antibody within 3 months after onset of KS; in 10, EBV infection could have been coincidental with the disease. Cytomegalovirus (CMV) was isolated from 9 patients with KS and 10 controls. A similar number of controls and patients had antibody to human herpesvirus 6 (HHV6); one patient seroconverted. None of the herpes viruses (EBV, CMV, HHV6, varicella-zoster virus, or herpes simplex virus) plays a unique or dominant role in the etiology or pathogenesis of KS in Hawaii.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156943     DOI: 10.1093/infdis/161.4.680

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus.

Authors:  Chun Lu; Yi Zeng; Zan Huang; Li Huang; Chao Qian; Guixia Tang; Di Qin
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

2.  Expression of CD180, a toll-like receptor homologue, is up-regulated in children with Kawasaki disease.

Authors:  Miyoko Imayoshi; Shuichi Yamamoto; Mamie Watanabe; Shinji Nishimura; Katsuya Tashiro; Masafumi Zaitsu; Hakaru Tasaki; Masao Kimoto; Yuhei Hamasaki; Eiichi Ishii
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

3.  Seasonality and temporal clustering of Kawasaki syndrome.

Authors:  Jane C Burns; Daniel R Cayan; Garrick Tong; Emelia V Bainto; Christena L Turner; Hiroko Shike; Tomisaku Kawasaki; Yosikazu Nakamura; Mayumi Yashiro; Hiroshi Yanagawa
Journal:  Epidemiology       Date:  2005-03       Impact factor: 4.822

4.  Ehrlichia chaffeensis and Rochalimaea antibodies in Kawasaki disease.

Authors:  M H Rathore; L L Barton; J E Dawson; R L Regnery; E M Ayoub
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

Review 5.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

Review 6.  Kawasaki disease: an update.

Authors:  Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.686

7.  Epstein-Barr virus antibodies in Kawasaki disease.

Authors:  Soon-Ju Lee; Kyung-Yil Lee; Ji-Whan Han; Joon-Sung Lee; Kyung-Tai Whang
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

Review 8.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

9.  An unusual pattern of arthritis in a child with Kawasaki syndrome.

Authors:  Ali Duzova; Rezan Topaloglu; Mehmet Keskin; Ugur Ozcelik; Gulten Secmeer; A Mazhar Tokgozoglu
Journal:  Clin Rheumatol       Date:  2004-01-08       Impact factor: 3.650

Review 10.  Kawasaki disease: 40 years after the original report.

Authors:  Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.